Skip to main content
OpenTrials
Completed

NCT Number: NCT01147432

Acute Response Capsaicin Flare Study

Prior to administering PF-04427429 to patients we wish to increase the understanding of functional effects associated with calcitonin gene related peptide (CGRP) pathways. This study will examine whether it is possible for a single dose of PF-04427429 to acutely attenuate a capsaicin induced flare response.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–50 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Pfizer Investigational Site

Brussels, B-1070, Belgium

About this study

Proof of mechanism in healthy volunteers

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male subjects between the ages of 18 and 50 years inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests.
  • Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the trial.
  • Skintype I-III with a distance from base of scaphoid to antecubital fossa >26cm on their forearms.

Exclusion criteria

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, genitourinary, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, symptomatic, seasonal allergies at time of dosing).
  • Use of biologics including any live vaccines within 3 months prior to screening or prior treatment with an antibody in a previous clinical trial or treatment with an immunoglobulin in the past 6 months.
  • 12-lead ECG demonstrating QTcF >450 msec at screening.
  • Subjects with scars or tattoos on the forearms, or with evidence of sunburn, or excessive hairy volar forearms.

Treatment and study plan

PF-04427429

Drug

Single dose IV infusion up to 300mg

Capsaicin challenge

Other

Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period

Placebo

Drug

Placebo IV infusion (saline) to be administered during two of the three treatment periods

EMLA positive control

Other

2g EMLA cream to be applied ONCE during study period 1

Primary outcomes

  1. Mean blood perfusion induced by capsaicin challenge, between 30 and 60 minutes post each administration of capsaicin

    Time frame: 7 weeks post first dose

Secondary outcomes

  1. Adverse Events including dose site reactions, blood pressure, pulse rate, ECG, ADA and laboratory safety

    Time frame: 12 weeks post final dose

  2. Plasma concentrations of free PF-04427429

    Time frame: 6 weekly following week 15

  3. Plasma concentrations of free and total CGRP

    Time frame: 6 weekly following week 15

  4. Mean blood perfusion induced by capsaicin challenge, between 40 and 60 minutes post each administration of capsaicin.

    Time frame: 7 weeks post first dose

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A Double Blind, Randomized, Placebo-Controlled, Third-Party Open, Modified Cross-Over Study To Examine The Acute Effect Of PF-04427429 On Capsaicin Flare Response In Healthy Volunteers Using EMLA Cream As Positive Control

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Jun 22, 2010
Registry last updated
Dec 21, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.